Finanzen von SAGE Therapeutics Inc (SAGE)SAGESAGE Therapeutics Inc

Evaluating the bottom line, SAGE Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -171.36%, while the net margin is -156.83%. These profitability ratios, combined with a Return on Equity (ROE) of -60.43%, provide a clear picture of how effectively SAGE converts its operational activities into shareholder value.

In the context of the broader market, SAGE competes directly with industry leaders such as TBPH and RZLT. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, SAGE's gross margin of 100.00% stands against TBPH's 100.00% and RZLT's N/A. Such benchmarking helps identify whether SAGE Therapeutics Inc is trading at a premium or discount relative to its financial performance.